

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SHIBUYA, et al.

Atty. Ref.: 249-323

Serial No. Unassigned

Group: Unassigned

Filed: January 26, 2004

Examiner: Unassigned

For: SUBSTANCE WHICH INHIBITS BIDING OF  
INFORMATION TRANSFER MOLECULE FOR 1175-  
TYROSINE PHOSPHORYLATED KDR/FLK-1 AND  
USAGES OF THE SAME

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

January 26, 2004

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits]  
N/C

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
N/C

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)]  
\$180.00

3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with  
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449. The listed documents are of record in the parent application Serial No. 09/969,037 such that further copies are not believed to be required. See, MPEP § 609.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; or

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)

a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of

SHIBUYA, et al.  
Serial No. Unassigned

this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. 249-323	SERIAL NO. Unassigned			
(Use several sheets if necessary)		APPLICANT SHIBUYA, et al.	FILING DATE January 26, 2004	GROUP Unassigned		
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,766,860	06/1998	TERMAN et al			
	4,816,567	3/1989	Cabilly			
	4,543,439	9/1985	Frackelton			
FOREIGN PATENT DOCUMENTS					TRANSLATION	
DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)						
	TERMAN et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor", Biochemical and Biophysical Research Communications, Vol. 187, No. 3, (1992), pp. 1579-1586					
	CUNNINGHAM, et al., "Interactions of FLT-1 and KDR with Phospholipase Cy: Identification of the Phosphotyrosine Binding Sites", Biochemical and Biophysical Research Communications, 240, pp. 635-639 (1997)					
	SAWANO, et al., "The Phosphorylated 1169-Tyrosine Containing Region of Flt-1 Kinase (VEGFR-1) Is a Major Binding Site for PLCy", Biochemical and Biophysical Research Communications 238, pp. 487-491 (1997)					
	KINASHI, et al., "Receptor Tyrosine Kinase Stimulates Cell-Matrix Adhesion by Phosphatidylinositol 3 Kinase and Phospholipase C-γ1 Pathways", Blood, Vol. 86, No. 6 (1995), pp. 2086-2090					
*Examiner		Date Considered				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.						

Examiner:

**Date Considered**

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**Form PTO-FB-A820 (Also PTO-1449)**